Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas

Fig. 2

Inhibition of methylation upregulates TMEFF2 mRNA expression in glioblastoma cells. a Bar graghBar gragh of the MSP analysis of GBM cells and SVG p12 cells. Error bars represent the SD of repeats of each cell. b Bar gragh of the RT-PCR analysis of GBM cells and SVG p12 cells. Error bars represent the SD of repeats of each cell. c The correlation between TMEFF2 methylation and mRNA expression in primary gliomas (n = 565). d Bar gragh of the MSP analysis of TMEFF2 in LN229 and T98G cells following treatment with DAC (5 µM) for 96 h. Error bars represent the SD of repeats of each cell. e Bar gragh of the RT-PCR analysis of TMEFF2 in LN229 and T98G cells following treatment with DAC (5 µM) for 96 h. Error bars represent the SD of repeats of each cell. f Bar gragh of the RT-PCR analysis of DNMT1 in LN229 and T98G cells treated with DNMT1 siRNA. Error bars represent the SD of repeats of each cell. g Bar gragh of the MSP analysis of TMEFF2 in LN229 and T98G cells following treatment with DNMT1 siRNA. Error bars represent the SD of repeats of each cell. h Bar gragh of the RT-PCR analysis of TMEFF2 in LN229 and T98G cells treated with DNMT1 siRNA. Error bars represent the SD of repeats of each cell. *P < 0.05, **P < 0.01, and ***P < 0.001

Back to article page
\